{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:03Z","timestamp":1791256743282,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K12HD047018"],"award-info":[{"award-number":["K12HD047018"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2598-1","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T16:11:14Z","timestamp":1469635874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib"],"prefix":"10.1186","volume":"16","author":[{"given":"Margaret E.","family":"Whicker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Sartorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S.","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"issue":"1","key":"2598_CR1","first-page":"10","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62(1):10\u201329.","journal-title":"CA: Cancer J Clin"},{"key":"2598_CR2","unstructured":"SEER Cancer Statistics Review, 1975\u20132010 [Internet]. Bethesda, MD.: National Cancer Institute; based on November 2012 SEER data submission, posted to the SEER web site, April 2013.\u00a0Available from: http:\/\/seer.cancer.gov\/csr\/1975_2010\/ . Accessed 29 Dec 2013."},{"issue":"17","key":"2598_CR3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck H, Meier W, Adams H, M\u00f6bus V, Costa S, et al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2598_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699\u2013708.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2598_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"34","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;34(1):1\u20136.","journal-title":"N Engl J Med"},{"issue":"24","key":"2598_CR6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"17","key":"2598_CR7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3310\/hta4170","volume":"4","author":"D Lister-Sharp","year":"2000","unstructured":"Lister-Sharp D, McDonagh M, Khan K, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess. 2000;4(17):110.","journal-title":"Health Technol Assess"},{"issue":"5","key":"2598_CR8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.2002.20.5.1158","volume":"20","author":"SA Cannistra","year":"2002","unstructured":"Cannistra SA. Is there a \u201cbest\u201d choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002;20(5):1158\u201360.","journal-title":"J Clin Oncol"},{"issue":"34","key":"2598_CR9","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23(34):5853\u20137.","journal-title":"Oncogene"},{"issue":"3","key":"2598_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1535-7163.MCT-07-0450","volume":"7","author":"V Benedetti","year":"2008","unstructured":"Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther. 2008;7(3):679\u201387.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2598_CR11","first-page":"2984","volume":"7","author":"A Reles","year":"2001","unstructured":"Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7(10):2984\u201397.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2598_CR12","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1242\/jcs.114.16.2903","volume":"114","author":"MA Lawlor","year":"2001","unstructured":"Lawlor MA, Alessi DR. PKB\/AKT: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114(16):2903\u201310.","journal-title":"J Cell Sci"},{"issue":"8","key":"2598_CR13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/CAD.0b013e3280cc2c6f","volume":"18","author":"J LoPiccolo","year":"2007","unstructured":"LoPiccolo J. Targeting AKT in cancer therapy. Anticancer Drugs. 2007;18(8):861\u201374.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2598_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ijc.23086","volume":"122","author":"M Fraser","year":"2008","unstructured":"Fraser M, Bai T, Tsang BK. AKT promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer. 2008;122(3):534\u201346.","journal-title":"Int J Cancer"},{"issue":"4","key":"2598_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ijc.2910640412","volume":"64","author":"A Bellacosa","year":"1995","unstructured":"Bellacosa A, De Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64(4):280\u20135.","journal-title":"Int J Cancer"},{"issue":"19","key":"2598_CR16","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.onc.1203598","volume":"19","author":"ZQ Yuan","year":"2000","unstructured":"Yuan ZQ, Sun M, Feldman R, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase\/AKT pathway in human ovarian cancer. Oncogene. 2000;19(19):2324\u201330.","journal-title":"Oncogene"},{"issue":"2","key":"2598_CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1535-7163.271.4.2","volume":"4","author":"D DeFeo-Jones","year":"2005","unstructured":"DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific AKT\/PKB family members. Mol Cancer Ther. 2005;4(2):271\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2598_CR18","unstructured":"Yan L. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009 American Association for Cancer Research;\u00a0Cancer Res. 2014;69(9 Supplement)."},{"issue":"7","key":"2598_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4161\/cbt.9.7.11100","volume":"9","author":"C Cherrin","year":"2010","unstructured":"Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, et al. An allosteric AKT inhibitor effectively blocks AKT signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther. 2010;9(7):493\u2013503.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"2598_CR20","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric AKT inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956\u201367.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2598_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/85798","volume":"27","author":"KK Khanna","year":"2001","unstructured":"Khanna KK, Jackson S. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247\u201354.","journal-title":"Nat Genet"},{"issue":"22","key":"2598_CR22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/jnci\/djh312","volume":"96","author":"RD Kennedy","year":"2004","unstructured":"Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The Role of BRCA1 in the Cellular Response to Chemotherapy. J Natl Cancer Inst. 2004;96(22):1659\u201368.","journal-title":"J Natl Cancer Inst"},{"key":"2598_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/117727190600100007","volume":"1","author":"A Horiuchi","year":"2006","unstructured":"Horiuchi A. BRCA1 expression is an important biomarker for chemosensitivity: suppression of BRCA1 increases the apoptosis via up-regulation of p53 and p21 during cisplatin treatment in ovarian cancer cells. Biomark Insights. 2006;1:49.","journal-title":"Biomark Insights."},{"issue":"24","key":"2598_CR24","doi-asserted-by":"publisher","first-page":"11704","DOI":"10.1158\/0008-5472.CAN-05-1214","volume":"65","author":"K Nojima","year":"2005","unstructured":"Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 2005;65(24):11704\u201311.","journal-title":"Cancer Res"},{"key":"2598_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","volume":"70","author":"ANJ Tutt","year":"2005","unstructured":"Tutt ANJ, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harbor Symp Quant Biol. 2005;70:139\u201348.","journal-title":"Cold Spring Harbor Symp Quant Biol."},{"issue":"8","key":"2598_CR26","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68(8):2581\u20136.","journal-title":"Cancer Res"},{"issue":"22","key":"2598_CR27","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth A. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785\u201390.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2598_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bcp.2009.01.008","volume":"77","author":"A Szanto","year":"2009","unstructured":"Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas Jr F, et al. PARP-1 inhibition-induced activation of PI-3-kinase-AKT pathway promotes resistance to taxol. Biochem Pharmacol. 2009;77(8):1348\u201357.","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"2598_CR29","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1158\/0008-5472.CAN-08-3009","volume":"68","author":"T Xiang","year":"2008","unstructured":"Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, et al. Negative regulation of AKT activation by BRCA1. Cancer Res. 2008;68(24):10040\u20134.","journal-title":"Cancer Res"},{"issue":"1","key":"2598_CR30","first-page":"217","volume":"30","author":"L Moro","year":"2007","unstructured":"Moro L, Arbini AA, Marra E, Greco M. Constitutive activation of MAPK\/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. Int J Oncol. 2007;30(1):217\u201324.","journal-title":"Int J Oncol"},{"issue":"22","key":"2598_CR31","doi-asserted-by":"publisher","first-page":"9404","DOI":"10.1158\/0008-5472.CAN-08-0861","volume":"68","author":"I Plo","year":"2008","unstructured":"Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res. 2008;68(22):9404\u201312.","journal-title":"Cancer Res"},{"key":"2598_CR32","doi-asserted-by":"crossref","unstructured":"Ratner E, Sartorelli A, Lin Z. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol. 2012;(Epub ahead of print)","DOI":"10.1097\/CCO.0b013e3283564230"},{"issue":"26","key":"2598_CR33","doi-asserted-by":"publisher","first-page":"27030","DOI":"10.1074\/jbc.M402056200","volume":"279","author":"ZP Lin","year":"2004","unstructured":"Lin ZP, Belcourt MF, Cory JG, Sartorelli AC. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(\u2212\/\u2212) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem. 2004;279(26):27030\u20138.","journal-title":"J Biol Chem"},{"issue":"3","key":"2598_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/1541-7786.MCR-13-0480","volume":"12","author":"ZP Lin","year":"2014","unstructured":"Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res. 2014;12(3):381\u201393.","journal-title":"Mol Cancer Res"},{"issue":"21","key":"2598_CR35","first-page":"6166","volume":"48","author":"SP Langdon","year":"1988","unstructured":"Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 1988;48(21):6166\u201372.","journal-title":"Cancer Res"},{"issue":"35","key":"2598_CR36","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1038\/onc.2010.245","volume":"29","author":"SL Cooke","year":"2010","unstructured":"Cooke SL, Ng CKY, Melnyk N, Garcia MJ, Hardcastle T, Temple J, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 2010;29(35):4905\u201313.","journal-title":"Oncogene"},{"key":"2598_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27.","journal-title":"Adv Enzyme Regul."},{"issue":"15","key":"2598_CR38","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.1073\/pnas.0507903103","volume":"103","author":"SB Goldfarb","year":"2006","unstructured":"Goldfarb SB, Kashlan OB, Watkins JN, Suaud L, Yan W, Kleyman TR, et al. Differential effects of Hsc70 and Hsp70 on the intracellular trafficking and functional expression of epithelial sodium channels. Proc Natl Acad Sci USA. 2006;103(15):5817\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"2598_CR39","doi-asserted-by":"publisher","first-page":"34473","DOI":"10.1074\/jbc.M503736200","volume":"280","author":"Z Zhu","year":"2005","unstructured":"Zhu Z, Ramos J, Kampa K, Adimoolam S, Sirisawad M, Yu Z, et al. Control of ASPP2\/53BP2L protein levels by proteasomal degradation modulates p53 apoptotic function. J Biol Chem. 2005;280(41):34473\u201380.","journal-title":"J Biol Chem"},{"issue":"3","key":"2598_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471\u201384.","journal-title":"Cell"},{"issue":"3","key":"2598_CR41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3892\/ol.2013.1132","volume":"5","author":"J Zhang","year":"2013","unstructured":"Zhang J, Zhang L, Shen L, Xu X, Yu H. Regulation of AKT gene expression by cisplatin. Oncol Lett. 2013;5(3):756\u201360.","journal-title":"Oncol Lett"},{"issue":"1","key":"2598_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","volume":"127","author":"E Jacinto","year":"2006","unstructured":"Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates AKT phosphorylation and substrate specificity. Cell. 2006;127(1):125\u201337.","journal-title":"Cell"},{"issue":"8","key":"2598_CR43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","volume":"10","author":"KJ Dedes","year":"2011","unstructured":"Dedes KJ. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10(8):1192.","journal-title":"Cell Cycle"},{"issue":"15","key":"2598_CR44","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"2598_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0968-0004(99)01413-9","volume":"24","author":"JE Haber","year":"1999","unstructured":"Haber JE. DNA recombination: the replication connection. Trends Biochem Sci. 1999;24(7):271\u20135.","journal-title":"Trends Biochem Sci"},{"issue":"47","key":"2598_CR46","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZS Siddik","year":"2003","unstructured":"Siddik ZS. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265\u201379.","journal-title":"Oncogene"},{"issue":"2","key":"2598_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T Chou","year":"2010","unstructured":"Chou T. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2598-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2598-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T23:47:57Z","timestamp":1656892077000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2598-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2598"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2598-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,27]]},"assertion":[{"value":"22 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"550"}}